Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCRL2 | O00421 | 20/20 | 0.79 |
| ▸ | CCR2 | P41597 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12032830 | 1.00 | CCRL2 (0.79) | CCRL2CCR2KCNH2 | |
| SCHEMBL12032834 | 0.91 | CCRL2 (0.79) | CCRL2CCR2KCNH2 | |
| SCHEMBL12032845 | 0.91 | CCRL2 (0.79) | CCRL2CCR2KCNH2 | |
| SCHEMBL12052248 | 0.88 | CCRL2 (1.00) | CCRL2CCR2KCNH2 | |
| SCHEMBL9999050 | 0.88 | CCRL2 (1.00) | CCRL2CCR2KCNH2 | |
| SCHEMBL9999053 | 0.88 | CCRL2 (1.00) | CCRL2CCR2KCNH2 | |
| SCHEMBL12034405 | 0.87 | CCRL2 (0.79) | CCRL2 | |
| SCHEMBL12034406 | 0.87 | CCRL2 (0.79) | CCRL2 | |
| SCHEMBL12032672 | 0.84 | CCRL2 (0.60) | CCRL2CCR2KCNH2 | |
| SCHEMBL12032669 | 0.84 | CCRL2 (0.60) | CCRL2CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICAL NV (BE) | 2013-11-21 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | CCRL2 6/4885CCR2 1/4885KCNH2 625/4885 |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | CCRL2 6/4885CCR2 1/4885KCNH2 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.